Lana Pine

Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.

Those with coexisting PsA and atopic dermatitis needed to switch to a higher number of biologics to achieve disease control.

The meta-analysis demonstrated gout with high blood uric acid levels significantly increases the risk of experiencing angina attacks.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

Patients in the moderate and high disease activity cohorts reported significantly reduced health state utility values and HRQoL scores compared with the reference cohort.

Patients in the Mediterranean diet group reported improvements in most fibromyalgia measures, including anxiety, fatigue, and disability scores.

The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.

At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.

This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.

The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

Patients placed in the intervention group reported significant improvements in gout knowledge levels over time compared with controls throughout the 24-week study period.

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.

The incidence of gout was 2.9 per 1000 patient-years, which dropped by 30% at the beginning of the COVID-19 pandemic.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Strategies designed to promote medication adherence were found in only 1 out of 3 websites.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.

NSAID use decreased the odds of a cardiovascular event by 12% in patients with gout.

Participants described the intervention as complete and coherent and would recommend this intervention to other patients.

The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.

Fresenius announced the immediate availability of its tocilizumab biosimilar, tocilizumab-aazg (Tyenne), in the US.